T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Pfizer Inc(PFE)

Dec 12, 2006
Likes the pharmaceutical industry, as it is undervalued. In the long term, it will come back. They will have to cut costs dramatically over the next several years. Cheap. Pays a 4% yield. Defensive. Won’t have dramatic moves.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$25.17

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 05, 2006
One for over 1, 2 and 3 years. Lost their major new blockbuster drug, but it wasn’t due on the market until Lipitor came off patent, 4 years out. Has $38 billion in cash and generates about $14 billion cash a year. Dividend yield of 3.9% and sees it going up a lot.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$24.82

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 05, 2006
What happened to their drug yesterday will probably mean the stock will stay down for awhile.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$24.82

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 04, 2006
(A Top Pick Aug 3/06. Down 4.2%.) Have sold their consumer products division and have a tremendous amount of cash coming in, giving them a very strong balance sheet. A Hold.
Photo of Ross HealyRoss Healy
Owned
Unlock Rating
$24.90

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 30, 2006
Pharmaceutical and health care area has been very difficult. Has done better in the last 6 months. A cheap stock.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$27.49

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Nov 22, 2006
Pharmaceutical sector is trading at very low valuations. Prefers Wyeth (WYE-N), which has a better growth profile, better portfolio of drugs. Also don’t have the problem of patent expirations that Pfizer does.
Photo of Alex RuusAlex Ruus
No
Unlock Rating
$27.10

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 07, 2006
His top choice in large pharmas is Eli Lilly (LLY-N). One of the major concerns that pharmacy companies have is patent expiration and generics coming in. This company is not well positioned to fend off generics.
Photo of Ian NakamotoIan NakamotoUnlock Rating
$27.29

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 31, 2006
(A Top Pick July 11/06. Up 12.8%.) 3.6 % dividend. Still more upside. But pipeline. Money continues to flow into the multinationals, which will benefit this company.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$26.65

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 23, 2006
3.4% dividend. The stock has been steadily rising over the last four months. Should be a core holding.
Photo of Rob CallanderRob Callander
Owned
Unlock Rating
$27.73

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 19, 2006
This group has been forgotten over the last 5 years as it wildly under-performed the market. They all went to virtually zero growth rate and now there is a pick up. There is cost cutting and they are under owned. Likes this space. This would not be his number one choice but it is okay.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$27.68

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 17, 2006
Reached his model price and he sold his holdings.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$27.72

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 16, 2006
Pipeline has been a little hurt because of competition, but the valuation is as cheap as it has been in 20 years.
Photo of John ZechnerJohn ZechnerUnlock Rating
$27.66

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 10, 2006
His favourite large drug stock. Has been beaten up pretty badly. Has a great product pipeline, even with patents coming off. Swimming in cash. Doing a share buyback and have increased their dividends.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$27.56

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 04, 2006
Very cheap. Pays a nice yield. There were some issues with management and there has been a change. The pharmaceutical industry as a whole is undervalued.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 27, 2006
The stock has increased since he picked it. They have raised their dividends. It has a high yield. He continues to own.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$28.41

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 601 to 615 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like